Evidence map›Paper›PMID 35203653›Full record

ArticleBiomedicines2022

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients.

Carlotta Cerva, Romina Salpini, Mohammad Alkhatib, Vincenzo Malagnino, Lorenzo Piermatteo, Arianna Battisti, Ada Bertoli, Jeff Gersch, Vera Holzmayer, Mary Kuhns and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Carlotta CervaI.N.M.I. "Lazzaro Spallanzani", 00149 Rome, Italy.ORCID 0000-0001-9060-7313
Romina SalpiniDepartment of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-2488-2082
Mohammad AlkhatibDepartment of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0003-0085-8990
Vincenzo MalagninoUnit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-6561-5298
Lorenzo PiermatteoDepartment of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-3500-0858
Arianna BattistiDepartment of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy.
Ada BertoliDepartment of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy.
Jeff GerschInfectious Disease Research, Abbott Diagnostics, Abbott Park, Green Oaks, IL 60064, USA.
Vera HolzmayerInfectious Disease Research, Abbott Diagnostics, Abbott Park, Green Oaks, IL 60064, USA.
Mary KuhnsInfectious Disease Research, Abbott Diagnostics, Abbott Park, Green Oaks, IL 60064, USA.
Gavin ClohertyInfectious Disease Research, Abbott Diagnostics, Abbott Park, Green Oaks, IL 60064, USA.
Ludovica FerrariUnit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.
Campogiani LauraUnit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.
Elisabetta TetiUnit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.
Maria CantonettiStem Cell Transplant Unit, Department of Hematology, Tor Vergata University, 00133 Rome, Italy.
William ArceseStem Cell Transplant Unit, Department of Hematology, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-2680-0984
Francesca Ceccherini-SilbersteinDepartment of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy.
Carlo-Federico PernoChildren Hospital "Bambino Gesù", 00165 Rome, Italy.
Massimo AndreoniUnit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.
Valentina SvicherDepartment of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy.
Loredana SarmatiUnit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.
University of Rome Tor Vergata · ITAbbott Fund · USBambino Gesù Children's Hospital · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of novel HBV markers in predicting Hepatitis B virus reactivation (HBV-R) in HBsAg-negative/anti-HBc-positive oncohaematological patients was examined. One hundred and seven HBsAg-negative/anti-HBc-positive oncohaematological patients, receiving anti-HBV prophylaxis for >18 months, were included. At baseline, all patients had undetectable HBV DNA, and 67.3% were anti-HBs positive. HBV-R occurred in 17 (15.9%) patients: 6 during and 11 after the prophylaxis period. At HBV-R, the median (IQR) HBV-DNA was 44 (27-40509) IU/mL, and the alanine aminotransferase upper limit of normal (ULN) was 44% (median (IQR): 81 (49-541) U/L). An anti-HBc > 3 cut-off index (COI) plus anti-HBs persistently/declining to <50 mIU/mL was predictive for HBV-R (OR (95% CI): 9.1 (2.7-30.2); 63% of patients with vs. 15% without this combination experienced HBV-R (

Indexed as

anti-HBc positivityantiviral prophylaxisHBV reactivationHSCTnew HBV markersoncohaematological patientsresolved HBV infection

Identifiers

PMID35203653
PMCPMC8962433
OpenAlexW4226018917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.